Translational Drug Development (TD2)
Ashley Mesa is a seasoned Clinical Data Manager at Translational Drug Development (TD2), where responsibilities include creating timelines for study tasks and ensuring compliance with Good Clinical Practice (GCP) and ICH Guidelines. Prior experience includes roles at the Children's Oncology Group, focusing on data collection protocol reviews and database accuracy, along with positions involving research coordination and electronic case report form (eCRF) design. Earlier, Ashley served as an Adjudicator at Shield HealthCare, handling claim denials, and completed an internship at Northridge Hospital Medical Center, where contributions to patient safety protocols were made. Educational credentials encompass a Bachelor of Science in Public Health Education and Promotion from California State University, Northridge, and an Associate of Arts in Liberal Arts and Sciences from College of the Canyons.
This person is not in any offices
Translational Drug Development (TD2)
Translational Drug Development (TD2) is an oncology-focused Contract Research Organization (CRO) that supports improved and accelerated development of medicines for life-threatening diseases. We help companies move their drugs through the critical stages of preclinical, regulatory and clinical trial processes. Our scientific depth, proactive problem solving, and strategic direction and advice increase the likelihood of positive outcomes that bring hope and a better quality of life to cancer patients and their families. TD2 was born from the Translational Genomics Research Institute (TGen) as a nonprofit in 2003. TGen’s deep scientific expertise and approach to interrogating the “omic” drivers of disease is at the heart of TD2’s heritage and has become the foundation upon which TD2 creates unique clinical strategies for its clients.